



Massachusetts Immunization Information System

**Vaccine Administration Record**

Patient: JEFFREY RIEL Birth Date: 04/30/1983 Gender: Male

Address: 745 WESTFORD ST, LOWELL, MA, 01851

| Vaccine Group                             | Vaccine    | Date Given<br>mo/day/yr | Dose | Route(PO, SC,<br>IM, ID, IN) | Site(RA, LA,<br>RT, LT) | Vaccine Lot# | Vaccine mfr.    | Date on VIS | Date VIS Given | Admin<br>By(Full name<br>/Initials) | Title |
|---|------------|-------------------------|------|------------------------------|-------------------------|--------------|-----------------|-------------|----------------|-------------------------------------|-------|
| Hepatitis B                               | HepB Adult | 07/29/2015              | 1    | IM                           | LA                      | 4T4GJ        | GlaxoSmithKline | 02/02/2012  | 07/29/2015     | MELANIE<br>MARTIN                   |       |
|   | HepB Adult | 01/15/2019              | 1    | IM                           | LA                      | 5YY7T        | GlaxoSmithKline | 07/20/2016  | 01/15/2019     | AMANDA<br>RUGGIERO                  |       |
| Diphtheria Tetanus<br>Pertussis           |            |                         |      |                              |                         |              |                 |             |                |                                     |       |
| Tetanus Diphtheria<br>Acellular Pertussis |            |                         |      |                              |                         |              |                 |             |                |                                     |       |
| Tetanus Diphtheria                        |            |                         |      |                              |                         |              |                 |             |                |                                     |       |
| Hib                                       |            |                         |      |                              |                         |              |                 |             |                |                                     |       |
| Poliomyelitis                             |            |                         |      |                              |                         |              |                 |             |                |                                     |       |
| Pneumococcal<br>Conjugate                 |            |                         |      |                              |                         |              |                 |             |                |                                     |       |
| Hepatitis A                               |            |                         |      |                              |                         |              |                 |             |                |                                     |       |
| Rotavirus                                 |            |                         |      |                              |                         |              |                 |             |                |                                     |       |
| Measles Mumps<br>Rubella                  |            |                         |      |                              |                         |              |                 |             |                |                                     |       |
| Meningococcal-<br>Conjugate               |            |                         |      |                              |                         |              |                 |             |                |                                     |       |

Jeffrey Riel

DOB: 4/30/83

SECTION D

HEALTHCARE PROVIDER ONLY

Complete BEFORE vaccine administration

- 1. I have reviewed the Patient Information and Screening Questions.
- 2. I have verified that this is the vaccine requested by the patient.
- 3. This vaccine is appropriate for this patient based on the Age Guidelines provided by federal and/or state regulations and company policies.
  - 3a. Does this patient have a high-risk medical condition?
    - If yes, please list medical condition(s):
- 4. The Vaccine NDC matches the NDC on the bottom of this VAR form and the NDC on the patient label. (Perform 3-way NDC match.)
- 5. I have verified the Expiration Date is greater than today's date and have entered the Lot # and Expiration Date in the field below.

Initial here: *AR*  
 Initial here: *AR*  
 Initial here: *AR*  
 Yes  No  
 Initial here: *AR*  
 Initial here: *AR*

For Shingrix®, Zostavax®, MMR® II, Varivax®, YF-Vax®, Menveo®, Imovax® and RabAvert®, ensure the vaccine is reconstituted following the package insert's instructions.

Lot #: 5299R Expiration Date: 9/14/21

For vaccines that have a diluent, complete the following:

Lot #: \_\_\_\_\_ Expiration Date: \_\_\_\_\_

SECTION E

Complete DURING the patient interaction

- 1. I have asked the patient to confirm their Name, DOB and Requested Vaccine and verified it matches the information on the VAR form.
- 2. I have reviewed the Screening Questions with the patient.
- 3. I have reviewed the VIS with the patient.

SECTION F

Complete AFTER vaccine administration

| Vaccine                             | NDC           | Manufacturer      | Dosage   | Site of administration | VIS published date |
|-------------------------------------|---------------|-------------------|----------|------------------------|--------------------|
| ENGERIX-B 20MCG/ML INJ, 1ML (ADULT) | 58160-0821-11 | GLAXO SMITH KLINE | 1.000 ML | LEFT                   |                    |

Clinician's name (print): *Asmark*

Clinician's signature: *[Signature]* Title: *Pharmacist*

If applicable, intern name (print): \_\_\_\_\_ Administration date: 4/6/19 Date VIS given to patient: 4/6/19

| Vaccine Reference Chart                  |                               |  | Notes |
|--|-------------------------------|--|-------|
| Vaccine                                  | Route                         | Dosage   |       |
| Influenza                                | Intramuscular                 | 0.5 mL   |       |
| Influenza (intradermal)                  | Intradermal                   | 0.1 mL   |       |
| Influenza (nasal)                        | Intranasal                    | 0.1 mL each nostril                                      |       |
| Hepatitis A                              | Intramuscular                 | 0.5 mL; Adolescents < 13 years<br>1 mL; Adults ≥19 years |       |
| Hepatitis B                              | Intramuscular                 | 0.5 mL; Adolescents < 19 years<br>1 mL; Adults ≥20 years |       |
| Hepatitis B (Heplisav-B)                 | Intramuscular                 | 0.5 mL   |       |
| Hepatitis A/B (Twinnix)                  | Intramuscular                 | 1 mL; Adults ≥18 years                                   |       |
| Human papillomavirus                     | Intramuscular                 | 0.5 mL   |       |
| Japanese encephalitis                    | Intramuscular                 | 0.5 mL   |       |
| Meningococcal ACYW-135                   | Intramuscular                 | 0.5 mL   |       |
| Meningococcal B                          | Intramuscular                 | 0.5 mL   |       |
| MMII (measles, mumps, rubella)           | Subcutaneous                  | 0.5 mL   |       |
| Pneumococcal (Prevnar 13)                | Intramuscular                 | 0.5 mL   |       |
| Pneumococcal (Pneumovax 23)              | Intramuscular or subcutaneous | 0.5 mL   |       |
| Polio                                    | Intramuscular or subcutaneous | 0.5 mL   |       |
| Rabies                                   | Intramuscular                 | 1 mL   |       |
| Shingles/herpes zoster (Zostavax)        | Subcutaneous                  | 0.65 mL  |       |
| Shingles/herpes zoster (Shingrix)        | Intramuscular                 | 0.5 mL   |       |
| Td (tetanus and diphtheria)              | Intramuscular                 | 0.5 mL   |       |
| Tdap (tetanus, diphtheria and pertussis) | Intramuscular                 | 0.5 mL   |       |
| Typhoid                                  | Intramuscular                 | 0.5 mL   |       |
| Vaccinia (chickenpox)                    | Subcutaneous                  | 0.5 mL   |       |
| Yellow fever                             | Subcutaneous                  | 0.5 mL   |       |

**Reminder**

1. Update the patient's record with any new allergy, health condition or primary care provider information.
2. Enter vaccine lot #, expiration date and site of administration, then scan the VAR form into the patient's record.